Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 120

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 120
---
, while others, such as Altimmune, are developing
intranasal vaccines that could offer advantages in terms of administration and mucosal immunity, directly competing with the administration
route proposed for our liposomal booster vaccine.

Emerging technologies focusing on universal coronavirus
vaccines aim to provide broad protection against multiple strains and variants of coronaviruses, including SARS-CoV-2 and its variants.
This approach could potentially outpace the variant-specific booster strategy by offering long-lasting immunity across a wider array of
potential future threats.

The competitive landscape is further complicated
by the global nature of the Coronavirus pandemic, which requires vaccines not only to be effective and safe but also accessible and scalable
to meet the vast demands of different countries and populations. Regulatory approvals, strategic alliances, manufacturing capabilities,
and distribution networks will play crucial roles in the successful deployment of Coronavirus vaccines, including our liposomal booster
vaccine.

While our liposomal booster vaccine is expected
to offer distinct advantages in terms of durability, broad-spectrum immunity, minimal side effects, it enters a highly competitive and
rapidly evolving market. The success of our vaccine will depend on our ability to demonstrate superior efficacy, safety, and ease of use
compared to existing and forthcoming Coronavirus vaccines, as well as our capacity to navigate regulatory, manufacturing, and distribution
challenges in a timely manner in additional antiviral product development programs.

Intellectual Property

We strive to protect
the intellectual property that we believe is important to our business, including seeking and maintaining patent protection intended to
cover the composition of matter of our product candidates, their methods of use, their methods of production, related technologies and
other inventions. In addition to patent protection, we also rely on trade secrets to protect aspects of our business that are not amenable
to, or that we do not consider appropriate for, patent protection, including certain aspects of technical know-how.

Our commercial success
depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies,
inventions and know-how related to our business, defend and enforce our intellectual property rights, particularly our patent rights,
preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of
others. We have discussed above our strategy with respect to the patent protection for each of our product candidates.

The patent positions
for companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage
claimed in a patent application can be significantly reduced